November 25, 2016 - By Adrian Mccoy · 0 Comments
The stock of Biocept Incorporated (NASDAQ:BIOC) registered an increase of 0.96% in short interest. BIOC’s total short interest was 1.02M shares in November as published by FINRA. Its up 0.96% from 1.01M shares, reported previously. With 366,800 shares average volume, it will take short sellers 3 days to cover their BIOC’s short positions. The short interest to Biocept Incorporated’s float is 13.53%. The stock increased 0.58% or $0.005 on November 25, hitting $0.845. About 33,894 shares traded hands. Biocept Inc (NASDAQ:BIOC) has declined 79.10% since April 22, 2016 and is downtrending. It has underperformed by 84.51% the S&P500.
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The company has a market cap of $14.64 million. The Firm develops and commercializes circulating tumor cell and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. It currently has negative earnings. The Company’s Target-Selector offering is based on an internally developed, microfluidics CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Out of 2 analysts covering Biocept Inc (NASDAQ:BIOC), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Biocept Inc has been the topic of 2 analyst reports since August 19, 2015 according to StockzIntelligence Inc. The stock of Biocept Inc (NASDAQ:BIOC) has “Buy” rating given on Monday, June 6 by Roth Capital. The rating was initiated by H.C. Wainwright with “Buy” on Wednesday, August 19.
Biocept, Inc., incorporated on June 28, 2013, is an early commercial-stage molecular oncology diagnostics company. The Firm develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s breast, lung and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on characteristics of their patients’ tumors.
More notable recent Biocept Inc (NASDAQ:BIOC) news were published by: Prnewswire.com which released: “Biocept to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to …” on September 09, 2016, also Prnewswire.com with their article: “Biocept Appoints Timothy C. Kennedy as Chief Financial Officer and Senior Vice …” published on July 27, 2016, Prnewswire.com published: “Biocept Reports 2016 Third Quarter Financial Results” on November 09, 2016. More interesting news about Biocept Inc (NASDAQ:BIOC) were released by: Prnewswire.com and their article: “Biocept Appoints David Moskowitz Vice President, Strategy & Corporate …” published on October 27, 2016 as well as Prnewswire.com‘s news article titled: “Biocept Announces Closing of $10 Million Public Offering of Common Stock and …” with publication date: October 19, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy